Reports
Global Tumour Necrosis Factor Inhibitor Drugs Market Size: By Type: Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars; By End Use: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Others; Regional Analysis; Competitive Landscape; 2024-2032
Global Tumour Necrosis Factor Inhibitor Drugs Market Outlook
The global tumour necrosis factor inhibitor drugs market attained a value of around USD 41.16 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of around 0.7% to reach USD 43.80 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is significantly being aided by the growing awareness among consumers about Tumour Necrosis Factor (TNF). North America is the leading region, whereas the Asia Pacific is expected to witness the fastest growth in the forecast period.
Market Segmentation
Tumour necrosis factor inhibitor are organic medicines derived from humans or animals’ tissues and most widely used by blocking the inflammatory substance, that is, the tumour necrosis factor in the body to stop inflammation and progression of the disease. It is recommended mainly for treating multiple inflammatory disorders, including rheumatoid arthritis and psoriasis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be divided into:
- Humira
- Enbrel
- Remicade
- Simponi/Simponi Aria
- Cimzia
- Biosimilars
The market can be broadly categorised based on its end-uses into:
- Rheumatoid arthritis
- Psoriasis
- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Hidradenitis Suppurativa
- Others
The EMR report looks into the regional markets of tumour necrosis factor inhibitor drugs like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The market for tumour necrosis factor inhibitor drugs is driven by the increased prevalence of several inflammatory disorders, like rheumatoid arthritis and inflammatory bowel disease in North America. Europe has also been a significant part of the global market due to a robust geriatric population, which is more vulnerable to inflammatory conditions. The increased incidences of different inflammatory diseases and the entrance in the market of the biosimilar are likely to increase both the availability and the usage of the tumour necrosis factor inhibitor drugs, which, in effect, will boost the market during the forecast period. In addition, low manufacturing costs in China and India have led to an increase in the number of plants attracting pharmaceutical and biotechnological giants from all over the world.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global tumour necrosis factor inhibitor drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- AbbVie, Inc. (NYSE: ABBV)
- Amgen, Inc.
- Johnson & Johnson Services, Inc.
- UCB S.A.
- Pfizer, Inc.
- Novartis International AG
- Merck & Co., Inc.
- Others
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, End Use, Region |
| Breakup by Type | Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars |
| Breakup by End Use | Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Crohn's Disease, Ulcerative colitis, Ankylosing Spondylitis, Juvenile idiopathic arthritis, Hidradenitis suppurativa, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | AbbVie, Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson Services, Inc., UCB S.A. (EBR: UCB), Pfizer, Inc. (NYSE: PFE), Novartis International AG (SWX: NOVN), Merck & Co., Inc. (NYSE: MRK), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Tumour Necrosis Factor Inhibitor Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Tumour Necrosis Factor Inhibitor Drugs Historical Market (2018-2023)
8.3 Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast (2024-2032)
8.4 Global Tumour Necrosis Factor Inhibitor Drugs Market by Type
8.4.1 Humira
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Enbrel
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Remicade
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Simponi/Simponi Aria
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 Cimzia
8.4.5.1 Historical Trend (2018-2023)
8.4.5.2 Forecast Trend (2024-2032)
8.4.6 Biosimilars
8.4.6.1 Historical Trend (2018-2023)
8.4.6.2 Forecast Trend (2024-2032)
8.5 Global Tumour Necrosis Factor Inhibitor Drugs Market by End Use
8.5.1 Rheumatoid Arthritis
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Psoriasis
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Psoriatic Arthritis
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Crohn’s Disease
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Ulcerative Colitis
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Ankylosing Spondylitis
8.5.6.1 Historical Trend (2018-2023)
8.5.6.2 Forecast Trend (2024-2032)
8.5.7 Juvenile Idiopathic Arthritis
8.5.7.1 Historical Trend (2018-2023)
8.5.7.2 Forecast Trend (2024-2032)
8.5.8 Hidradenitis Suppurativa
8.5.8.1 Historical Trend (2018-2023)
8.5.8.2 Forecast Trend (2024-2032)
8.5.9 Others
8.6 Global Tumour Necrosis Factor Inhibitor Drugs Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Tumour Necrosis Factor Inhibitor Drugs Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Tumour Necrosis Factor Inhibitor Drugs Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Tumour Necrosis Factor Inhibitor Drugs Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 AbbVie, Inc. (NYSE: ABBV)
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Amgen, Inc. (NASDAQ: AMGN)
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Johnson & Johnson Services, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 UCB S.A. (EBR: UCB)
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Pfizer, Inc. (NYSE: PFE)
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Novartis International AG (SWX: NOVN)
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Merck & Co., Inc. (NYSE: MRK)
16.2.7.1 Company Overview
16.2.7.2 Product Portfolio
16.2.7.3 Demographic Reach and Achievements
16.2.7.4 Certifications
16.2.8 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Tumour Necrosis Factor Inhibitor Drugs Market: Key Industry Highlights, 2018 and 2032
2. Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Type (USD Billion), 2018-2023
3. Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Type (USD Billion), 2024-2032
4. Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by End Use (USD Billion), 2018-2023
5. Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by End Use (USD Billion), 2024-2032
6. Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Region (USD Billion), 2018-2023
7. Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Region (USD Billion), 2024-2032
8. North America Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2023
9. North America Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2024-2032
10. Europe Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2023
11. Europe Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Latin America Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Latin America Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Global Tumour Necrosis Factor Inhibitor Drugs Market Structure
Key Questions Answered in the Report
In 2023, the global tumour necrosis factor inhibitor drugs market attained a value of nearly USD 41.16 billion.
The market is projected to grow at a CAGR of 0.7% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 43.80 billion by 2032.
The major drivers of the industry, such as the growing awareness among consumers about TNF, increased prevalence of several inflammatory disorders, and low manufacturing costs, are expected to aid the market growth.
The key market trend guiding the industry growth includes the growing development and manufacture of new products.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
The leading types of tumour necrosis factor inhibitor drugs in the industry are Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars.
The major end uses of these drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and hidradenitis suppurativa, among others.
The major players in the industry are AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., UCB S.A., Pfizer, Inc., Novartis International AG, and Merck & Co., Inc., among others.
Analyst Review
The global tumour necrosis factor inhibitor drugs market attained a value of USD 41.16 billion in 2023, driven by the increased incidences of different inflammatory diseases. Aided by the development of new products, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 0.7%. The market is projected to reach USD 43.80 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the tumour necrosis factor inhibitor drugs industry can be segmented into Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. On the basis of end uses, the industry is divided into rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others. The major regional markets for tumour necrosis factor inhibitor drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above market include AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., UCB S.A., Pfizer, Inc., Novartis International AG, Merck & Co., Inc., and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER